Literature DB >> 6088584

Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line.

R C McEvoy, J Andersson, S Sandler, C Hellerström.   

Abstract

Mice were examined for the presence of splenocytes specifically cytotoxic for a rat insulinoma cell line (RIN) during the induction of diabetes by streptozotocin (SZ) in multiple low doses (Multi-Strep). Cytotoxicity was quantitated by the release of 51Cr from damaged cells. A low but statistically significant level of cytolysis (5%) by splenocytes was first detectable on day 8 after the first dose of SZ. The cytotoxicity reached a maximum of approximately 9% on day 10 and slowly decreased thereafter, becoming undetectable 42 d after SZ was first given. The time course of the in vitro cytotoxic response correlated with the degree of insulitis demonstrable in the pancreata of the Multi-Strep mice. The degree of cytotoxicity after Multi-Strep was related to the number of effector splenocytes to which the target RIN cells were exposed and was comparable to that detectable after immunization by intraperitoneal injection of RIN cells in normal mice. The cytotoxicity was specific for insulin-producing cells; syngeneic, allogeneic, and xenogeneic lymphocytes and lymphoblasts, 3T3 cells, and a human keratinocyte cell line were not specifically lysed by the splenocytes of the Multi-Strep mice. This phenomenon was limited to the Multi-Strep mice. Splenocytes from mice made diabetic by a single, high dose of SZ exhibited a very low level of cytotoxicity against the RIN cells. The cytotoxic response was also quantitated in splenocytes from control and Multi-Strep mice (10 d after the first dose of SZ) before and after culture with mitomycin-treated RIN cells in the presence of T cell growth factor (TCGF). The cytotoxicity of the Multi-Strep splenocytes was enhanced more than fivefold after such culture, suggesting the proliferation of an effector cell that could be stimulated and supported in vitro by TCGF. These results support the hypothesis that cell-mediated anti-beta cell autoimmunity may play a role in the destruction of the beta cells in this animal model. The stimulation of this response by TCGF may provide a tool by which enough cytotoxic effector cells could be obtained to establish their possible direct pathogenetic role in the induction of insulin-dependent diabetes. In addition, such cells will be a valuable tool to define the specific beta-cell antigens that may direct the highly selective cell-mediated destruction of these cells in experimental models and, perhaps, in human insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088584      PMCID: PMC425225          DOI: 10.1172/JCI111487

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients.

Authors:  A C MacCuish; S J Urbaniak; C J Campbell; L J Duncan; W J Irvine
Journal:  Diabetes       Date:  1974-08       Impact factor: 9.461

2.  Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity.

Authors:  S Kataoka; J Satoh; H Fujiya; T Toyota; R Suzuki; K Itoh; K Kumagai
Journal:  Diabetes       Date:  1983-03       Impact factor: 9.461

3.  The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in the mouse in vivo and in vitro.

Authors:  S Sandler; A Andersson
Journal:  Diabetologia       Date:  1982-10       Impact factor: 10.122

4.  Insulin-dependent diabetes: a disease of autoaggression.

Authors:  S W Huang; N K Maclaren
Journal:  Science       Date:  1976-04-02       Impact factor: 47.728

5.  Protection by dimethyl urea against hyperglycaemia, but not insulitis, in low-dose streptozotocin-induced diabetes in the mouse.

Authors:  S Sandler
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

6.  Genetic influence of the streptozotocin-induced insulitis and hyperglycemia.

Authors:  A A Rossini; M C Appel; R M Williams; A A Like
Journal:  Diabetes       Date:  1977-10       Impact factor: 9.461

7.  Studies of streptozotocin-induced insulitis and diabetes.

Authors:  A A Rossini; A A Like; W L Chick; M C Appel; G F Cahill
Journal:  Proc Natl Acad Sci U S A       Date:  1977-06       Impact factor: 11.205

8.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

9.  The effect of immunosuppression on streptozotocin-induced diabetes in C57BL/KsJ mice.

Authors:  E H Leiter; W G Beamer; L D Shultz
Journal:  Diabetes       Date:  1983-02       Impact factor: 9.461

10.  Diabetes susceptibility of BALB/cBOM mice treated with streptozotocin. Inhibition by lethal irradiation and restoration by splenic lymphocytes.

Authors:  S G Paik; M L Blue; N Fleischer; S Shin
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

View more
  35 in total

1.  Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice.

Authors:  G Kantwerk-Funke; V Burkart; H Kolb
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 2.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

3.  A longitudinal ultrastructural study of pancreatic cellular damage in murine streptozotocin diabetes.

Authors:  E R Richens; F M Tungekar; K Behbehani
Journal:  Acta Diabetol Lat       Date:  1988 Jul-Sep

4.  microRNA-30c reduces plasma cholesterol in homozygous familial hypercholesterolemic and type 2 diabetic mouse models.

Authors:  Sara Irani; Jahangir Iqbal; W James Antoni; Laraib Ijaz; M Mahmood Hussain
Journal:  J Lipid Res       Date:  2017-11-09       Impact factor: 5.922

Review 5.  Mouse models of diabetic neuropathy.

Authors:  Phillipe D O'Brien; Stacey A Sakowski; Eva L Feldman
Journal:  ILAR J       Date:  2014

6.  SIRT1 regulates macrophage self-renewal.

Authors:  Francesco Imperatore; Julien Maurizio; Stephanie Vargas Aguilar; Clara J Busch; Jérémy Favret; Elisabeth Kowenz-Leutz; Wilfried Cathou; Rebecca Gentek; Pierre Perrin; Achim Leutz; Carole Berruyer; Michael H Sieweke
Journal:  EMBO J       Date:  2017-07-12       Impact factor: 11.598

7.  Transfected rat islet tumour cells express mouse major histocompatibility complex class I antigens functionally. Applicable as "pseudo-syngeneic" targets in the multiple low-dose streptozotocin diabetes model.

Authors:  P Serup; J Schøller
Journal:  Diabetologia       Date:  1989-07       Impact factor: 10.122

8.  Destruction of conditional insulinoma cell lines in NOD mice: a role for autoimmunity.

Authors:  P Cattan; D Rottembourg; S Cottet; I Tardivel; P Dupraz; B Thorens; C Boitard; J C Carel
Journal:  Diabetologia       Date:  2003-03-25       Impact factor: 10.122

9.  pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.

Authors:  Haichen Wang; Michael L James; Talaignair N Venkatraman; Lawrence J Wilson; Polina Lyuboslavsky; Scott J Myers; Christopher D Lascola; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

10.  Vascular permeability of pancreatic islets after administration of streptozotocin.

Authors:  S Sandler; L Jansson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.